A Plain Language Summary of the Molecular Changes in the Tumors of People With Braf V600E-Mutant Colorectal Cancer in the Beacon Study

Authors

Scott Kopetz
Danielle A Murphy
Jie Pu
Fortunato Ciardiello
Jayesh Desai
Eric Van Cutsem
Harpreet Singh Wasan
Takayuki Yoshino
Hedieh Saffari
Xiaosong Zhang
Phineas Hamilton
Tao Xie
Rona Yaeger
Josep Tabernero

Publication Date

6-1-2025

Journal

Future Oncology

DOI

10.1080/14796694.2025.2498880

PMID

40340632

PMCID

PMC12150622

PubMedCentral® Posted Date

5-9-2025

PubMedCentral® Full Text Version

Post-print

Abstract

What is this summary about?This summary discusses the genetic and molecular changes in tumors of participants with BRAF V600E–mutant metastatic colorectal cancer who were treated with encorafenib plus cetuximab, with or without binimetinib, in the BEACON study.

What were the results?Encorafenib plus cetuximab, with or without binimetinib, reduced the risk of participants dying compared with cetuximab plus chemotherapy, regardless of genetic or molecular colorectal cancer subtypes.The study also found genetic and molecular changes in the participants’ tumors during treatment that were associated with how long they lived.

What do the results of the study mean?The types of genetic and molecular changes that occur during treatment in participants’ tumors can affect their response to treatment with BRAF and MEK inhibitors.

Published Open-Access

yes

Recommended Citation

Kopetz, Scott; Murphy, Danielle A; Pu, Jie; et al., "A Plain Language Summary of the Molecular Changes in the Tumors of People With Braf V600E-Mutant Colorectal Cancer in the Beacon Study" (2025). Faculty, Staff and Student Publications. 4629.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/4629